© 2007 European Society for Medical Oncology
breast cancer |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
1 Department of Medical Oncology
2 Department of Orthodontics
3 Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
* Correspondence to: Prof. L. A. deGraffenried, Division of Medical Oncology, MSC 7884, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. Tel: +1-210-567-4739; Fax: +1-210-567-6687; E-mail: degraffenri{at}uthscsa.edu
Background: Resistance to endocrine therapy is a major impediment in breast cancer therapeutics. The Phosphatidylinositol-3-OH kinase (PI3K)/Protein kinase B (Akt/PKB) kinase signaling pathway has been implicated in altering breast cancer response to multiple therapies. How Akt modulates response is an area of significant clinical relevance.
Methods: We have used an in vitro model to discern the effects of robust Akt activity on breast cancer cellular response to endocrine therapies.
Results: High levels of Akt activity confer resistance to the aromatase inhibitor Letrozole (Let) and the selective estrogen receptor (ER) down-regulator Fulvestrant (ICI). Akt-induced resistance is not due to failure of these endocrine agents to inhibit estrogen receptor 
activity. Instead, resistance is characterized by altered cell cycle and apoptotic response. Cotreatment with low concentrations of the mTOR inhibitor RAD-001 and either Let or ICI restores response of the resistant cells to levels observed in the responsive cells treated with either Let or ICI as a single agent.
Conclusions: Our preliminary findings in experiments with RAD-001 indicate that cotreatment with mTOR inhibitors and either Let or ICI reverses the Akt-mediated resistance and restores responsiveness to antiestrogens. Concurrent ER and mTOR inhibition is therefore an effective strategy to overcome growth factor-induced resistance and bears significant implications for optimal clinical development of these agents in breast cancer treatment.
Key words: Akt, breast cancer, endocrine therapy, mTOR
Received for publication August 23, 2006. Revision received February 26, 2007. Accepted for publication March 30, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S Dawood and M Cristofanilli Endocrine resistance in breast cancer: what really matters? Ann. Onc., August 1, 2007; 18(8): 1289 - 1291. [Full Text] [PDF]
|
|